IMC is developing a promising treatment for fibromyalgia, IBS, ME/CFS, and a broad range of other conditions that show strong evidence of sharing the same underlying pathophysiology. IMC has 9 potential compounds in the pipeline, 2 of which are highlighted below.
IMC-1IMC’s lead compound is IMC-1, which has completed a successful phase 2 trial and has been granted a Fast Track Designation by the FDA for the treatment of fibromyalgia.
IMC-1, a novel proprietary fixed dose combination medication, was studied to confirm the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia symptoms or recurrence. IMC-1 is a combination anti-viral treatment that is designed to suppress this suspected virus and thus alleviate fibromyalgia symptoms.
STAGE OF DEVELOPMENT DESCRIPTION COMPLETION OBSERVATIONAL FIELD EVIDENCE Combining and utilizing anti-viral compounds that consistently resulted in positive, sustained outcomes for patients PROOF-OF-CONCEPT ESTABLISHED The role of HSV-1 in chronic gastrointestinal disorders associated with fibromyalgia PROPRIETARY SCIENTIFIC PLATFORM Development of novel anti-viral compounds designed to inhibit replication and reactivation of the HSV-1 life cycle at different, critical stages PHASE 1 CLINICAL TRIAL N/A (application of pre-approved, established molecules) PHASE 2 CLINICAL TRIAL
The "FAST" Study
A study of IMC-1 In patients with fibromyalgia IMC-1 PHASE 3 CLINICAL TRIAL* NDA/ PRODUCT LABELING PHASE IV/
*IMC is currently working with the FDA to meet all of the necessary requirements to start the IMC-1 phase 3 trials for the management of fibromyalgia.
IMC has its second novel product NRP-1, a proprietary throat spray designed to treat viral pharyngitis, a large unmet medical need and cause of most cases of pharyngitis. NRP-1 will also provide much needed relief for cancer patients undergoing head and neck radiation plagued with disabling oral mucositis/pharyngitis. This first-of-its-kind spray delivers the medication which then adheres to the posterior pharynx despite repeated swallows and saliva.